Filing Flows › Amgen (AMGN) › Q3 2026 › vs Q3 2025
Amgen (AMGN) Q3 2026 vs Q3 2025 (year over year)
Amgen's revenue rose $808M (+8%) from $9.6B in Q3 2025 to $10.4B in Q3 2026. The biggest changes: Product sales +$746M (+8%); BLINCYTO +$104M (+27%). Operating margin 35.8% against 26.4% (+9.4 pts).
Amgen, Q3 2026: revenue $10.4B (+8% year over year), operating margin 35.8%, net earnings $3.9B, operating cash flow $4.2B. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 35.8% | 26.4% | +9.4 pts |
| Net margin | 37.3% | 33.7% | +3.6 pts |
| Free cash flow margin | 35.3% | 44.4% | -9.2 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Product sales | $9.9B | $9.1B | $746M | +8% |
| BLINCYTO | $496M | $392M | $104M | +27% |
| Revenue | $10.4B | $9.6B | $808M | +8% |
| Other income, net | $976M | $1.4B | −$419M | -30% |
| Operating profit | $3.7B | $2.5B | $1.2B | +47% |
| Costs & expenses | $6.7B | $7.0B | −$376M | -5% |
| Pre-tax earnings | $4.7B | $3.9B | $765M | +20% |
| Cost of revenue | $2.8B | $3.1B | −$294M | -10% |
| Research & development | $2.1B | $1.9B | $211M | +11% |
| SG&A | $1.7B | $1.7B | −$40.0M | -2% |
| Other operating costs | $76.0M | $329M | −$253M | -77% |
| Net earnings | $3.9B | $3.2B | $648M | +20% |
| Income tax | $822M | $705M | $117M | +17% |
| Depreciation & amortization | $1.1B | $1.3B | −$185M | -14% |
| Share-based compensation | $128M | $127M | $1.0M | +0.8% |
| Working capital & other | $873M | −$34.0M | $907M | — |
| Operating cash flow | $4.2B | $4.7B | −$443M | -9% |
| Free cash flow (OCF − capex) | $3.7B | $4.2B | −$594M | -14% |
| Capital expenditures | $587M | $436M | $151M | +35% |
Questions
How much did Amgen's revenue grow year over year in Q3 2026?
Amgen's revenue rose $808M (+8%) from $9.6B in Q3 2025 to $10.4B in Q3 2026.
What drove Amgen's revenue change in Q3 2026?
Product sales +$746M (+8%); BLINCYTO +$104M (+27%).